Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210027/S018

QDOT MICRO System

Biosense Webster, Inc. · Decision date Sep 10, 2026

MEDTECHLEDGER EXPLANATIONP210027/S018

What did the FDA decide?

The FDA record P210027/S018, with a decision of OK30 dated 2026-09-10, is a 30-Day Notice supplement to PMA P210027. The stated purpose is "to implement a repackaging and relabeling operation," and the listed supplement reason is a process change involving manufacturer, sterilizer, packager or supplier. The product code is OAE, describing a percutaneous cardiac ablation catheter for treatment of atrial fibrillation, and the applicant is Biosense Webster, Inc.

Beyond that purpose statement, the source does not specify which packaging or labeling elements change, where the operation occurs, or what validation supports it. This notice does not approve the QDOT MICRO System as a whole; it concerns a change to an existing approval identified by P210027, and the OK30 decision is a regulatory action rather than independent evidence of safety or clinical effectiveness. Any effect on the device's performance is not established by these fields.

The specialty field lists Cardiovascular, and the supplement type limits the scope to the reported process change. The supplied text does not detail the repackaging method, materials, or labeling content, so those specifics remain unknown here.

FDA approval order statement

to implement a repackaging and relabeling operation
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 10, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210027/S018
Regulatory pathway
PMA supplement
Product code
OAE
Decision code
OK30
Decision date
Sep 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.

Product code
OAE
FDA device class
3

For the original device and its historical approval scope, see PMA P210027. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210027 · Original PMA

    QDOT MICRO System

  2. P210027/S018 received

    Application receipt date recorded by FDA.

  3. P210027/S018 · FDA decision

    30-Day Notice

  4. P210027/S019 · Related supplement

    QDOT MICRO BI-DIRECTIONAL NAVIGATION CATHETER; QDOT MICRO UNI-DIRECTIONAL NAVIGATION CATHETER

Timeline entries are records held by MedtechLedger for P210027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210027

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA approvalNov 23, 2022FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA

Explore the linked device profile

Other records with product code OAE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records